 The Food and Drug Administration late Friday said that AstraZeneca Plcs AZN, 1.42 COVID-19 drug Evusheld may not provide protection against developing the illness in people exposed to XBB.1.5, one of the newest COVID subvariants. Thats because XBB.1.5 is similar to other subvariants not neutralized by Evusheld, the FDA said. 